Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors Oct 8, 2024 09:00AM
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 Oct 4, 2024 09:05AM
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1 Oct 2, 2024 04:05PM
Kineta (KA) Delisting to OTC Sep 20, 2024 06:16AM
Kineta, Inc Transitioning from Nasdaq to OTC Markets Sep 19, 2024 06:23PM


Aug 19, 2024 09:00AM Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
Jul 8, 2024 06:30AM Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
May 15, 2024 04:02PM Kineta (KA) Reports Q1, Provides Update on Phase 1/2 VISTA-101 Trial
May 15, 2024 04:01PM Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
Mar 21, 2024 04:02PM Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
Feb 29, 2024 08:32AM Kineta (KA) Announces Restructuring and Exploration of Strategic Alternatives
Feb 29, 2024 08:30AM Kineta Announces Restructuring and Exploration of Strategic Alternatives
Feb 29, 2024 07:10AM Kineta (KA) to Explore Strategic Alternatives, Cuts Staff, Terminates CEO